
All you need to know about: vitiligo
Our skin is the primary victim of sun exposure, and as the summer sun grows harsher each year, protecting it becomes more imperative than ever. For people with vitiligo, a condition marked by depigmented patches of skin, this protection is especially crucial.
Vitiligo is a chronic autoimmune condition that leads to the loss of skin pigment, resulting in patches that are lighter than one's natural skin tone. Some of the patches may fully turn milky white, and when vitiligo affects areas on the body with hair, the hair in those spots may also turn white or silver. The condition develops when the body's immune system attacks and destroys melanocytes — the cells responsible for producing melanin, the pigment that gives skin its colour.
Vitiligo cannot be cured, but there are treatments to slow down its progression. The condition doesn't cause physical pain or pose significant dangers, but it can lead to severe sunburn if the skin is exposed to sunlight without adequate protection. Wearing sunscreen, therefore, is a must.
Moreover, the stigma and shame often associated with vitiligo can create emotional challenges for those living with it.
This International Skin Pigmentation Day on May 25, let's take a closer look at vitiligo: what causes it, how one can get affected by it, and the ways to treat it.
What are the symptoms?
Vitiligo is characterised by depigmented areas of skin. When these areas are smaller than 1 cm, they're called macules; if they're larger, they're called patches.
The condition often begins with a few small white macules or patches that may slowly spread across the body. It commonly first appears on the hands, forearms, feet, and face, but it can also affect any part of the body, including the mucous membranes (such as those in the mouth, nose, genitals, and rectum), as well as the eyes and inner ears.
The extent of pigment loss varies from person to person: some individuals develop only a few small patches, while others experience more widespread depigmentation. Some also experience itchy skin before the depigmentation starts. The symptoms generally start before age 30, but some may also experience it before age 20.
What causes vitiligo and who can get it?
Vitiligo is caused by the lack of melanin in the body. It is an autoimmune condition, which means the body's immune system mistakes healthy cells — in this case, melanocytes — for harmful invaders like viruses or bacteria. This results in the production of antibodies to destroy the melanocytes.
According to studies, stress or even environmental triggers, like exposure to UV radiation or toxic chemicals, can also play a role in the occurrence of vitiligo.
About 1% of the population experience vitiligo, according to a Pfizer article, and anyone can develop this skin condition, regardless of their gender or colour.
A Cleaveland Clinic article also indicates that about 30% of vitiligo cases are genetic, meaning, they can be inherited from your family members. However, genetic predisposition with respect to vitiligo is more complex as there are multiple simultaneous risk factors at play, according to a 2017 study published in PubMed Central.
Those with certain existing autoimmune conditions, such as Addison's disease, psoriasis, rheumatoid arthritis, thyroid disease, and type 1 diabetes, are more prone to developing vitiligo, according to a National Institute of Health article.
What are the risks involved?
While vitiligo itself isn't life-threatening, it can cause one's skin to be more sensitive to sunlight, and in turn, result in sunburns.
People with vitiligo may also experience slight changes in their eyes, such as abnormalities in the retina or variations in iris colour. In rare cases, inflammation can occur in the retina or iris, though it typically doesn't affect vision.
Those living with the condition may also have a higher risk of developing other autoimmune disorders, such as hypothyroidism, diabetes, or anaemia.
The mental health challenges posed by vitiligo can be significant. People with the condition may have low self-esteem and tend to avoid social situations. This emotional strain can also contribute to anxiety and depression.
What are the treatment options?
Since vitiligo isn't curable, treatment options primarily focus on slowing the progression of the condition or enabling repigmentation (restoring the colour of the skin) or depigmentation (removing all colour, ensuring a uniform skin tone).
Medications such as corticosteroids and calcineurin inhibitors may help decelerate depigmentation or even stimulate the regrowth of melanocytes.
Light therapy, which involves directing ultraviolet B (UVB) lights or medical-grade lasers at one's depigmented skin, helps to restore colour to some extent. Depigmentation therapy, on the other hand, involves the use of monobenzone, a medication applied to the areas of skin that still have pigment.
There are surgical options too, such as using skin grafts from one part of the body to restore or cover affected areas elsewhere. This may, however, not always yield desired results.
Therapy, to deal with the emotional effects of living with vitiligo, is also recommended by healthcare professionals.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
02-06-2025
- Time of India
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )

Time of India
28-05-2025
- Time of India
Trump Warns Netanyahu Over Iran Strike Plans
'Died Within 8 Hrs Of Taking Pfizer Vaccine': Chilling Covid Testimony By Dr McCullough A COVID-19 variant that has led to a resurgence in cases in China has now been discovered in the United States according to the U.S. Centers for Disease Control and Prevention. Reports say that a CDC spokesperson has indicated that less than 20 such cases have been found in the United States so far. The new Covid strain comes even as a high-stakes Senate hearing has triggered shockwaves over mRNA COVID-19 vaccine risks. Lawmakers and top medical experts are questioning federal agencies on adverse events and accountability. Explosive testimonies have put vaccine-related deaths and myocarditis under renewed scrutiny. Watch the full testimony of Dr Peter McCullough (President, McCullough Foundation) here. 5.4K views | 1 day ago

Time of India
28-05-2025
- Time of India
Delhi's Wettest May In 124 Years: What's Causing Violent Storms & Extreme Rains?
'Died Within 8 Hrs Of Taking Pfizer Vaccine': Chilling Covid Testimony By Dr McCullough A COVID-19 variant that has led to a resurgence in cases in China has now been discovered in the United States according to the U.S. Centers for Disease Control and Prevention. Reports say that a CDC spokesperson has indicated that less than 20 such cases have been found in the United States so far. The new Covid strain comes even as a high-stakes Senate hearing has triggered shockwaves over mRNA COVID-19 vaccine risks. Lawmakers and top medical experts are questioning federal agencies on adverse events and accountability. Explosive testimonies have put vaccine-related deaths and myocarditis under renewed scrutiny. Watch the full testimony of Dr Peter McCullough (President, McCullough Foundation) here. 5.2K views | 19 hours ago